LAMP3 antibody
- Known as:
- LAMP3 (anti-)
- Catalog number:
- orb125919
- Product Quantity:
- 100 ug
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- LAMP3 antibody
Related genes to: LAMP3 antibody
- Gene:
- LAMP3 NIH gene
- Name:
- lysosomal associated membrane protein 3
- Previous symbol:
- -
- Synonyms:
- LAMP, TSC403, DC-LAMP, DCLAMP, CD208
- Chromosome:
- 3q27.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-29
- Date modifiied:
- 2016-10-05
Related products to: LAMP3 antibody
Related articles to: LAMP3 antibody
- Cervical cancer is among the most prevalent gynecological malignancies globally, and its inherent molecular heterogeneity remains a persistent obstacle to uniform treatment efficacy and patient survival. Lysosome-mediated cell death (LDCD) has recently emerged as a mechanistically distinct form of regulated cell death with growing relevance in tumor biology, influencing both oncogenic progression and responsiveness to therapy. Nevertheless, its functional significance in cervical cancer and its interactions with the tumor microenvironment (TME) at single-cell resolution remain insufficiently characterized. - Source: PubMed
Publication date: 2026/05/30
Cheng YurongLi XuanYan Dong - Early-life psychosocial stress (ELS) has lasting effects on physical and mental health, yet the biological mechanisms linking ELS to midlife cognitive function remain incompletely understood. Chronic, low-grade inflammation has been proposed as a key pathway, but prior studies have examined only a narrow set of markers. - Source: PubMed
Publication date: 2026/05/25
Wang XiaolingHarris Ryan ALiu YutaoGoldstein Felicia CMansuri AsifhusenMcDowell Jennifer ESu Shaoyong - Dendritic Cell Vaccines (DCVax) can induce tumor-specific immune responses, yet their clinical activity remains limited and poorly understood. We sought to identify cellular and molecular features within the vaccine product that are associated with clinical response to monocyte-derived DC vaccines in metastatic melanoma. - Source: PubMed
Publication date: 2026/05/23
Tazzari MarcellaCarloni SilviaBulgarelli JennyPignatta SaraBocchini MartinePiccinini ClaudiaAngeli DavideTebaldi MichelaAzzali IreneTumedei Maria MaddalenaPiccinini FilippoTauceri FrancescaLimarzi FrancescoNicolini FabioBochicchio Maria TeresaUrbini MilenaFoschi GiovanniRomanini Nicolade Rosa FrancescoGranato Anna MariaPancisi ElenaPetrini MassimilianoRidolfi Laura - Recent studies reveal that inorganic nanoparticles (NPs) can alter allergic skin reactions in a contact hypersensitivity (CHS) mouse model. Specifically, negatively charged silica (SiO) NPs suppressed the response whereas manganese doped titanium dioxide (mTiO) exacerbated it. Mast cells are critically important in transducing the CHS response. In this study we investigated the effect of SiO and mTiO NPs on bone marrow derived mast cell (BMMC) activation markers, degranulation and cytokine release. Sensitized BMMC were exposed to NPs alone or NPs plus antigen. Cytokines (IL-6, IL-13, TNF-α) and degranulation (β-hexosaminidase) studies were performed. Flow cytometry was used to follow cell surface activation markers including FcεRI, CD63 (LAMP-3), and CD107a (LAMP-1). Transmission Electron Microscopy (TEM) studies were preformed to assess NP endocytosis. Results found that mTiO NPs were cytotoxic to BMMC in a dose- and time-dependent manner. SiO NPs showed minimal cytotoxicity up to 100 µg/ml. In the absence of antigen the NPs had limited effect on sensitized BMMC degranulation or cytokine release. However, in the presence of antigen, 30 min co-culture studies (NP plus antigen) showed that SiO NPs protect against degranulation, and they suppressed the expression of cell surface activation markers whereas mTiO NPs exacerbated these. - Source: PubMed
Publication date: 2026/05/21
Pineda Jessica PerezDeLouise Lisa A - We evaluated the biomarker potential of Sig27, a 27-gene panel originating from prostate cancer, in breast cancer (BC). Orthotopic BC tumors were generated in Balb/c mice using 4T1 cells expressing either empty vector (EV) or the gain-of-function PCSK9 mutant D374Y. Sig27 expression was analyzed in mouse tumors, 13,103 primary BCs, 60 metastases, and 780 normal breast tissues. Its prognostic value was assessed in BC, 20 other cancer types, and in tumor-associated macrophages (TAMs), regulatory T cells (Tregs), and exhausted CD8⁺ T cells (CD8Tex). Sig27 was significantly altered in D374Y vs. EV tumors and showed consistent dysregulation in primary and metastatic BCs. It stratified BC fatality risk comparably to OncotypeDX and MammaPrint. Notably, Sig27 predicted poor prognosis across 21 cancer types. In 2716 BCs, OncotypeDX and MammaPrint correlated with mitotic progression, while Sig27 was predominantly associated with immune regulation. In bulk RNA-seq datasets (n = 6734), Sig27 and its key genes (FPR3, LAMP3, and FAM65B) were strongly associated with multiple immune checkpoints (ICs). Single-cell RNA-seq data revealed their primary expression in TAMs, and to a lesser extent in Tregs and CD8Tex. These associations were enhanced in Sig27IM, formed by FPR3, LAMP3, and FAM65B. Their expression, along with Pd-l1, Lgals9, and Pvrig, was upregulated in D374Y tumors. Furthermore, Sig27 and Sig27IM predicted pathologic complete response in BC treated with PD1 and PD-L1 inhibitors; Sig27IM displayed robust correlations with established immune-signatures: CTL, Merck18, TIDE, and STAT1_sig. Collectively, Sig27 captures BC's immune properties, which likely contribute to its biomarker potential. - Source: PubMed
Publication date: 2026/05/18
Su YingyingDong YingZhang TaoTang Damu